Skip to main content

Table 1 Studies and clinical trials of inflammasome inhibitors in cancer

From: Inflammasome inhibitors: promising therapeutic approaches against cancer

Drug

Target

Effective cancer type

Clinical trials

Reference

Thalidomide

Caspase-1

Prostate cancer

Phase II

[54]

Multiple myeloma

Phase III

[55]

Anakinra

IL-1R

Melanoma

N/A

[56]

Breast cancer

[57]

Multiple myeloma

Phase II

[58]

P2X7R antagonist

P2X7R

Prostate cancer

N/A

[59]

Pancreatic ductal adenocarcinoma (PDAC)

[60, 61]

Osteosarcoma

[62]

Multiple myeloma

[63]

Head and neck squamous cell carcinoma

[64]

Colorectal cancer

[65]

Basal cell carcinoma

Phase I

[66]

Parthenolide

NF-κB

Gastric cancer

N/A

[67]

Colorectal cancer

[68]

Pancreatic adenocarcinoma

[69]

Nasopharyngeal carcinoma

[70]

Andrographolide

NF-κB

Insulinoma

N/A

[71]

Colorectal cancer

[72,73,74]

Breast cancer

[75, 76]

Multiple myeloma

[77]

Canakinumab

IL-1β

Lung cancer

Phase III (undergoing)

[78]